About Us
Company History
The Team
Executive Management
Board of Directors
Scientific Advisory Board
Partners
|
Product
|
Science
Scientific Overview
Epitope-based Approach
Scientific Publications
|
Influenza
The Flu Virus
The Flu and Global Health
Useful Links
|
News & Media
Press Releases
Events & Presentations
BiondVax in the News
Press Kit
|
Investor Relations
Stock Information
Ownership Structure
Financial Reports
Regulatory Filings
|
Careers
|
Contact Us
Home
>> Investor Relations
Investor Relations
Investor Relations
Stock Information
Ownership Structure
Financial Reports
Regulatory Filings
Investor Relations
Home
Recent Financial Reports
30 November 2009
Board of Directors Report - 3rd Quarter 2009
Auditor's Report - 3rd Quarter 2009
26 November 2009
Shelf Prospectus
View all financial reports
►
Recent Investor Presentations
18 February 2010
BiondVax - Corporate Presentation, February 2010
Recent News
8 March 2010
BiondVax Reports Positive Interim Safety Results from Second Phase I/II Universal Influenza Vaccine Trial
24 February 2010
BiondVax signs Term Sheet for up to $7m through a 3 year Standby Equity Distribution Agreement (SEDA) with Yorkville Advisor
9 December 2009
Successful Stock Offering
7 December 2009
Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals’ Universal Flu Vaccine
View all news stories
►
Recent Events
Tel Aviv Stock Exchange - BioMed Conference
7 December 2009, Tel Aviv, Israel
World Influenza Congress, Europe 2009
8 December 2009, Brussels, Belgium
